Clinical Report: 2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer

Overview

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD, discuss new antibody–drug conjugate (ADC) options for first-line treatment of triple-negative breast cancer (TNBC). The supplied context reports 2026 FDA approvals of sacituzumab govitecan as monotherapy for patients ineligible for PD-1/PD-L1 inhibitor-based therapy and with pembrolizumab for PD-L1-positive disease.

Background

TNBC is described by Erica Michelle Stringer-Reasor, MD, as an aggressive subtype with limited treatment options. The related ASCO discussion addresses current treatment approaches and future directions, including neoadjuvant chemotherapy as the preferred approach to treatment. The 2026 material focuses on first-line ADC treatment options for advanced TNBC. The supplied regulatory context distinguishes treatment according to eligibility for immunotherapy and PD-L1 status.

Data Highlights

Key Findings

• The article context identifies first-line ADC treatment options in TNBC as the subject of discussion by Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD.
• On June 24, 2026, the FDA approved sacituzumab govitecan monotherapy for adults with unresectable locally advanced or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor-based therapy.
• The FDA also approved sacituzumab govitecan with pembrolizumab for adults with PD-L1-positive tumors with CPS ≥10, as determined by an FDA-authorized test.
• In ASCENT-03, median PFS was 9.7 months with sacituzumab govitecan and 6.9 months with physician’s-choice chemotherapy in previously untreated advanced TNBC not eligible for PD-(L)1 inhibitors.
• In ASCENT-04/KEYNOTE-D19, meeting abstracts reported median PFS of 11.2 months with sacituzumab govitecan plus pembrolizumab and 7.8 months with chemotherapy plus pembrolizumab.
• The related ASCO education-session account describes TNBC as aggressive with limited treatment options and identifies neoadjuvant chemotherapy as the preferred approach to treatment.

Clinical Implications

The supplied FDA context specifies first-line sacituzumab govitecan regimens according to immunotherapy eligibility and, for the pembrolizumab combination, PD-L1 CPS status. The combination indication requires PD-L1 testing with an FDA-authorized test, according to the supplied regulatory summary.

Conclusion

The 2026 material centers on first-line ADC options for advanced TNBC, including sacituzumab govitecan alone or with pembrolizumab in the specified patient groups. The reported phase 3 results provide the clinical-trial context for these FDA actions.

Related Resources & Content

1. FDA, FDA Drug Approvals and Databases, 2026 — FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
2. The ASCO Post, 2023 — Current Management of and Future Possibilities for Triple-Negative Breast Cancer
3. ASCO Publications, 2016 — Triple negative breast cancer: Demographic and clinicopathological properties
4. ASCO Publications — Triple negative breast cancer: Demographic and clinicopathological properties.
5. ASCO Publications — Triple-negative breast cancers: Biomarkers and outcomes.
6. FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
7. Current Management of and Future Possibilities for Triple-Negative Breast Cancer
8. FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer | FDA
9. FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer | FDA
10. Updated NCCN Guidelines Recommend First-Line Sacituzumab Govitecan–Based Regimens for TNBC | OncLive